Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
AGSAV301
Exforge 10/160
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Adult males 20 to 40 years at screening.
- body weight ≥ 45kg and within ± 20% of the ideal body weight : Ideal body weight = (height [cm] - 100) x 0.9
- Be able to collect blood for study and visit for follow-up period
- Subject who agrees to participate in this study and give written informed consent
Exclusion Criteria:
- Have history of significant hepatic, renal, gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
- Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or surgery(except for Appendectomy, Hernia repair) affected the absorption of medications
- Inappropriate in Screening test (interview, vital sigh, BP, 12-lead ECG, laboratory test etc.)
- Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of amlodipine or valsartan
- drug abuse, or have a history of drug abuse showed a positive for the screening test on urine : amphetamine, barbiturate, cocaine, opiates, benzodiazepines, cannabinoids, methadone etc.
- Subject who takes herbal medicine within 30 days, ethical drug within 14 days, OTC within 7 days before the beginning of administration of investigational drug
- Unusual diet affected the absorption, distribution, metabolism, excretion of medications
- Subject who treated with any investigational drugs within 60 days before the administration of investigational drug
- Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
- Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
- Subject who have taken habitually caffeine (caffeine > 5 units/day)
- Subject who have drunken habitually (alcohol > 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
- positive for Hepatitis B, Hepatitis C, HIV or Syphilis
- Blood Pressure is not in the range of "140 > sitting SBP ≥ 90mmHg, 90 > sitting DBP ≥ 60mmHg"
- Pulse rate is not in the range of "95 > sitting Pulse Rate ≥ 45bpm (beats per minute)"
- AST, ALT, total bilirubin over twice of reference range
- Subjects deemed ineligible by investigator based on other reasons
Sites / Locations
- Asan Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
AGSAV301
Exforge 10/160
Arm Description
Outcomes
Primary Outcome Measures
Area Under Curve (AUC)
Cmax
Secondary Outcome Measures
AUC (inf)
tmax
t(1/2β)
Full Information
NCT ID
NCT01536353
First Posted
February 15, 2012
Last Updated
November 24, 2015
Sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd
Collaborators
Asan Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01536353
Brief Title
Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301
Official Title
A Single Dose, Randomized, Open-label, 2x2 Crossover Study to Evaluate the Bioavailability and Safety of AGSAV301 Tablet in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
August 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd
Collaborators
Asan Medical Center
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the bioavailability and safety of AGSAV301 tablet in healthy male volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AGSAV301
Arm Type
Experimental
Arm Title
Exforge 10/160
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
AGSAV301
Intervention Description
tablet, q.d.
Intervention Type
Drug
Intervention Name(s)
Exforge 10/160
Intervention Description
Tablet, q.d.
Primary Outcome Measure Information:
Title
Area Under Curve (AUC)
Time Frame
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours
Title
Cmax
Time Frame
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120,168 hours
Secondary Outcome Measure Information:
Title
AUC (inf)
Time Frame
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120,168 hours
Title
tmax
Time Frame
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours
Title
t(1/2β)
Time Frame
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adult males 20 to 40 years at screening.
body weight ≥ 45kg and within ± 20% of the ideal body weight : Ideal body weight = (height [cm] - 100) x 0.9
Be able to collect blood for study and visit for follow-up period
Subject who agrees to participate in this study and give written informed consent
Exclusion Criteria:
Have history of significant hepatic, renal, gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or surgery(except for Appendectomy, Hernia repair) affected the absorption of medications
Inappropriate in Screening test (interview, vital sigh, BP, 12-lead ECG, laboratory test etc.)
Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of amlodipine or valsartan
drug abuse, or have a history of drug abuse showed a positive for the screening test on urine : amphetamine, barbiturate, cocaine, opiates, benzodiazepines, cannabinoids, methadone etc.
Subject who takes herbal medicine within 30 days, ethical drug within 14 days, OTC within 7 days before the beginning of administration of investigational drug
Unusual diet affected the absorption, distribution, metabolism, excretion of medications
Subject who treated with any investigational drugs within 60 days before the administration of investigational drug
Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
Subject who have taken habitually caffeine (caffeine > 5 units/day)
Subject who have drunken habitually (alcohol > 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
positive for Hepatitis B, Hepatitis C, HIV or Syphilis
Blood Pressure is not in the range of "140 > sitting SBP ≥ 90mmHg, 90 > sitting DBP ≥ 60mmHg"
Pulse rate is not in the range of "95 > sitting Pulse Rate ≥ 45bpm (beats per minute)"
AST, ALT, total bilirubin over twice of reference range
Subjects deemed ineligible by investigator based on other reasons
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyun-Seop Bae, M.D., Ph.D.
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301
We'll reach out to this number within 24 hrs